Articles tagged with Cancer Medication
Researchers discovered that triplatinNC changes the geometry of heparan sulfate, blocking its splitting and preventing tumor cell migration. This finding opens possibilities for designing anti-metastatic platinum complexes.
Small cell lung cancer cells lack surface protein NKG2DL, allowing them to hide from immune system. Researchers found that expressing this protein on their surfaces can trigger an immune response and lead to smaller tumors with more activated immune cells.
Researchers at Northwestern University have developed a novel therapy that uses synthetic nanoparticles to trigger the destruction of lymphoma cells by depriving them of cholesterol. This approach has potential for targeting other cancers with an appetite for cholesterol, such as kidney and ovarian cancer.
Researchers at Kanazawa University have found that combining alectinib with ixazomib, a proteasome inhibitor, restores the efficacy of alectinib in patients with NSCLC who develop secondary TP53 mutations. This combination therapy has shown promising results in preclinical trials.
Researchers at the University of Cincinnati have developed a new combination therapy that combines radiation therapy with an approved drug to make it more effective in treating head and neck cancer. The study found that the drug alone reduced cancer cell growth by up to 90% and increased the efficacy of radiation treatment by 40%.
Researchers develop bioengineered microscale organotypic models (BMOMs) to address cancer treatment limitations. BMOMs can be integrated with microscopes and sensors to monitor biological processes in high resolution, reducing the need for animal models.
A new study from Penn Medicine reveals that patients with inactive cancer and not currently undergoing treatments are significantly more likely to experience severe COVID-19 illness. The research highlights the importance of COVID-19 mitigation measures, such as social distancing and mask-wearing, and vaccinations for all patients.
Researchers propose improved tumor models to personalize cancer treatment by analyzing patient-derived samples and clinical trials data. This approach aims to accelerate the pace of cancer research, facilitating faster and more reliable drug testing.
A randomized clinical trial found that pre-surgery chemotherapy did not improve survival rates in early-stage pancreatic cancer patients, but it is a safer alternative. The study paved the way for further treatment testing and molecular analysis of tumor tissue.
A new drug targeting enzymes involved in myristoylation has shown promise in treating both breast and blood cancers. Researchers found that patients with specific enzyme NMT2 were more likely to die, and the drug slowed tumour growth by 90% in mice with human breast cancer.
Scientists have discovered a link between nicotine and the spread of breast cancer cells into the lungs, which can lower survival rates by 33%. Nicotine exposure creates an environment ripe for metastatic growth, attracting immune cells that promote tumor growth.
Researchers at Johns Hopkins Medicine have developed a new experimental therapy that prevents premature birth using nanosized particles of drugs. The treatment decreases contractions in uterine muscles and could be a clinical option for preventing preterm labor.
Researchers have developed ultra-small nanomedicines that stably deliver oligonucleotides to refractory cancers, such as brain tumors and pancreatic cancer. These nanomedicines use Y-shaped block copolymers and nucleic acid drugs, achieving high permeability in cancer tissues and stability in the bloodstream.
A new method, D2O-CANST-R, allows for rapid and precise tracking of metabolic changes in cancer cells at the single-cell and single-organelle level. This approach has the potential to reveal the metabolism in a cancer cell with very fine details and distinguish between effective and ineffective drugs.
Researchers have identified two drugs that work synergistically to promote significant anti-leukemia activity when combined, but only weakly effective when used alone. The study found that the combination of MDM2 inhibitors and BET inhibitors unleashes the full anti-cancer activity of p53 in AML patients.
Researchers at Duke-NUS Medical School have designed armoured immune cells that can target hepatocellular carcinoma, a common type of primary liver cancer, without being affected by immunosuppressive drugs used to prevent organ rejection. The T cells remain effective for up to four days before regaining sensitivity to the drugs.
The event aims to address current and future challenges in cancer drug development through panel discussions with eminent speakers. Delegates will learn about key areas for innovation and collaboration to improve cancer treatment.
Researchers at UNH discovered a new inhibitor drug combination that effectively reduces growth and kills WM cancer cells, offering more treatment options. Adding venetoclax or panabinostat to BET inhibitors shows improved efficacy in treating Waldenström macroglobulinemia.
A new study stratified tumors into 112 subtypes and found Master Regulator proteins control the transcriptional state of each subtype. Targeting these proteins with novel drug classes could benefit a larger fraction of patients. The analysis identified 24 Master Regulator modules, mechanistically controlling cancer cell survival.
Researchers from Duke-NUS Medical School in Singapore and Columbia University in the US have solved the molecular structure of Wnt proteins and their dedicated transporter protein, Wntless. The study reveals a promising drug target for cancer treatment, with a made-in-Singapore anti-cancer drug, ETC-159, showing potential.
A new study found that up to 20% of glioblastomas are fueled by overactive mitochondria, making them potentially treatable with current clinical trial drugs. Researchers discovered four types of brain cancer, including the mitochondrial subtype, which has a slightly better prognosis.
The study identified three distinct subtypes of HPV-negative head and neck squamous cell carcinomas (HNSCCs) with varying prognoses. The subtypes CIN, Basal, and Immune showed potential for different treatments, including CDK4/6 inhibitors, monoclonal antibodies targeting EGFR, and immune checkpoint inhibitors.
Researchers at Indiana University School of Medicine have discovered a promising treatment approach for preventing acute graft-versus-host disease, a common complication of blood stem cell transplantation. The study found that using the oral drug sitagliptin reduces the risk of GVHD by inhibiting immune T cell activation.
A study identifies three molecular subtypes in HNSCC, suggesting different therapy options for EGFR, CDK, and immunotherapy. Biomarkers like EGFR ligands and Rb phosphorylation status may help select patients for targeted treatments.
A new UCL study found that combining heat treatment with chemotherapy delivered via magnetic nanoparticles killed cancer cells more effectively than chemotherapy alone. The therapy showed synergistic effects, enhancing the effectiveness of both treatments when combined. Heat treatment can reduce side effects by targeting only cancer ce...
Researchers found that cancer cells promote blood clot formation to enter the brain tissue. Inhibiting clotting factors thrombin and von Willebrand factor reduced brain metastases in mice. The study suggests targeting this process with drugs for preventing brain metastases in high-risk patients.
A biologist has created software tools to model cancer pathways and predict the efficacy of cancer drugs. The project aims to develop targeted treatments that target specific signaling networks in cancer cells, reducing harm to normal cells.
Cancer cells use a molecule called ENPP1 to destroy warning signals that trigger an immune response, making them resistant to immunotherapy. Flipping this switch off could increase sensitivity to checkpoint inhibitors and improve treatment outcomes for various cancers.
A triple drug combination of irinotecan, cetuximab, and vemurafenib has shown better tumor response rates and longer cancer-free periods compared to a two-drug combination in patients with metastatic colorectal cancer. The treatment targets the BRAF protein directly and blocks cancer growth by targeting epidermal growth factor receptor.
Researchers have discovered that free-floating circular DNA fragments called ecDNA form in cancer cells and drive gene amplification to generate drug resistance. Combining chemotherapeutic drugs with molecules that prevent ecDNA formation can inhibit its emergence and reduce drug resistance.
Studies reveal that income level, employment, housing location, medical insurance, education, tobacco and alcohol use, diet and obesity, access to medical care are common causes of poorer outcomes in both Black patients with cancer and COVID-19 patients.
The FDA Oncology Center of Excellence has developed initiatives to address the unique challenges faced by cancer patients during COVID-19. The center provides guidance and support to healthcare professionals, enabling them to provide high-quality cancer care despite the pandemic's impact.
A new drug combination combining a widely used diabetes treatment with an experimental cancer drug has shown significant improvements in blood glucose control and weight loss in mice. The combination treatment enhanced insulin secretion and reduced body weight, paving the way for clinical studies.
A study from Scripps Research Institute has identified an enzyme that limits blood vessel growth, providing insights into potential medicines to kill tumors and stop cancer from spreading. The findings also may enable new interventions for healthy blood-vessel development in people with heart disease and other conditions.
Researchers developed a compound that inhibits the growth of cancer cells by targeting mitochondrial function, without severe side effects. The compound prevents genetic information within mitochondria from being read, starving cancer cells into dying.
Researchers discovered that abatacept reduced severity of myocarditis in genetic mouse model and human patients. The study provides a potential new treatment option for patients with immune-related side effects from immunotherapies.
Researchers from Lithuania's three top universities have developed a method to improve anticancer drug delivery by combining low-intensity pulsed ultrasound with microbubbles. The team found that the rate of microbubble survival time is the best indicator for determining sonoporation efficiency.
Researchers from Tokyo University of Science modified mesenchymal stem cells to carry anti-cancer drugs and deliver them to target cancers, showing efficient delivery in mouse models. The study suggests a faster and more effective method for delivering drugs to tumor cells.
Researchers found a drug used to treat pulmonary hypertension significantly reduced tumor cell migration and invasion, and showed promise in slowing breast cancer progression. The study aims to conduct clinical trials with patients undergoing chemotherapy to further investigate the treatment's effectiveness.
A new RNA drug-discovery tool called Chem-CLIP-Fragment Mapping has been developed to address the challenge of 'undruggable' proteins. The tool uses functionalized fragments that can bind to RNAs and modify their structure, enabling the design of medicines against previously untreatable diseases.
Researchers at Cleveland Clinic's Taussig Cancer Institute have identified a potential new class of targeted drugs to treat myeloid leukemias, including those with the common TET2 gene mutation. The new pharmacological strategy, TETi76, preferentially targets and eliminates leukemia cells with TET2 mutations in preclinical models.
ReceptorNet, a deep-learning algorithm developed by Salesforce Research, can determine hormone-receptor status from inexpensive tissue images, improving treatment decision-making for breast cancer patients. This technology has the potential to make high-quality therapies more accessible globally.
Researchers found non-pharmacological interventions such as fan therapy and bilevel ventilation to be effective in improving breathlessness in patients with advanced cancer. In contrast, medications like opioids had limited impact on symptom relief.
Women who receive mastectomy and reconstructive surgery are at increased risk of developing persistent use of opioids and sedative-hypnotic drugs. The study found that 13.1% of patients become new persistent opioid users after surgery, while 6.6% develop persistent sedative-hypnotic use.
A recent study reveals unique mutation patterns in the genes PIK3CA, GNAS, SMAD3, and TSC2 among young patients with appendiceal cancer. These findings suggest potential for targeted therapies, such as alpelisib, which have already been approved for advanced breast cancer.
New research uses microbubbles to deliver anticancer drugs directly to tumour sites, improving efficacy and reducing harm to healthy cells. The technology allows for targeted delivery of highly toxic drugs with precision, increasing potency and reducing side effects.
Scientists have discovered a way to control the flow of liquids using magnetotactic bacteria, which can be used to transport cancer drugs directly to tumors. The bacteria produce an effect similar to that of a micropump, allowing for precise control over the movement of active substances.
A new cancer therapy approach combines gemcitabine chemotherapy with celecoxib, an anti-inflammatory medication, to activate the immune system and fight cancer. The combination has shown potential in improving the percentage of patients who respond to immunotherapy drugs.
Researchers have discovered that isatuximab, a monoclonal antibody approved for multiple myeloma, can effectively treat relapsed refractory AL amyloidosis. The study showed an overall response rate of 77% among patients who received the treatment.
The combination of venetoclax with chemotherapy improves outcomes for patients with AML and MDS, with a promising overall response rate and acceptable safety profile. Venetoclax also demonstrates efficacy in treating high-risk MDS when combined with azacitidine.
Researchers at Huntsman Cancer Institute have identified a potential drug combination to treat uveal melanoma by targeting genes GNAQ and GNA11. The study showed that using trametinib and hydroxychloroquine together led to more cell deaths than the drugs alone.
A comprehensive map of approximately 200 kinases has been created to assist researchers in designing molecules that target specific kinases for destruction. This could lead to more effective cancer therapies by targeting kinases that play a key role in tumor cell proliferation.
Researchers at Memorial Sloan Kettering Cancer Center have identified a new target for aggressive lung adenocarcinomas driven by the KEAP1 and STK11 mutations. By inhibiting ferroptosis, these tumors rely on this blockade to grow and survive.
A new study from Harvard Medical School forecasts the impact of eliminating race from kidney function formulas on Black patients with kidney disease. The analysis suggests that removing race-based adjustments may lead to earlier diagnoses and better access to care, but also restricts access to certain medications and treatments.
A machine learning model developed in Finland can identify best cancer drug combinations to selectively kill specific cancer cells with unique genetic or functional profiles. The AI model accurately predicts how different drug combinations inhibit particular cancer cells, paving the way for more effective cancer treatments.
Researchers report factors preventing effective launch of oncology biosimilars, including market share struggles and patent litigation lawsuits. The 'Pay-for-Delay' strategy by AMGEN and Genentech/Roche holds the market hostage.
Researchers at Indiana University School of Medicine published a study using a donated tumor from Tyler Trent, a college student who died from bone cancer. The team found that a combination therapy significantly slowed tumor growth in models, leading to hopes for new treatments and improved outcomes for children with osteosarcoma.
UTEP researchers will use 3D bioprinting to study the progression of diabetes and its effects on the heart, aiming to develop targeted treatments for cardiomyopathy. The project also aims to screen cardiac toxicity in common drugs used by patients with type 2 diabetes.
A new study found that cancer drug treatment registrations in the UK increased by June 2020, following 'rapid' NHS guidance. The initial decrease in April was largely reversed by May and June, with a significant increase in neoadjuvant breast cancer therapy registrations.
A new therapeutic PD-1 cancer vaccine has been shown to be safe and effective in an animal study, activating both B- and T-cell functions to promote tumor clearance. The vaccine is targeted to block signaling pathways crucial for tumor growth and maintenance, offering a promising approach to immunotherapy.